Cullinan Therapeutics to Join Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company dedicated to developing targeted therapies that are modality-agnostic, has announced that its executive team will be attending several significant investor conferences in the near future.
Key Executives Participating in Conferences
Nadim Ahmed, the Chief Executive Officer, along with Jeffrey Jones, M.D., M.B.A., the Chief Medical Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. This event is scheduled for an upcoming Thursday in New York, starting at 4:05 p.m. EDT.
Furthermore, both executives will also engage in another fireside chat at the 2024 Cantor Global Healthcare Conference, which will take place in New York on a Thursday at 10:20 a.m. EDT.
Webcast Availability
For those interested in following along, webcasts of both the Morgan Stanley and Cantor fireside chats will be accessible in the Events and Presentations section of the Company’s investor relations website.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is committed to establishing new standards of care for patients through the strategic development of a diverse portfolio of clinical-stage assets. These assets aim to inhibit critical disease drivers or harness the immune system to target and eliminate diseased cells, addressing a range of autoimmune diseases and various cancers.
The company's portfolio encompasses a wide array of modalities, with the goal of creating best-in-class or first-in-class treatment options. With extensive expertise in oncology, immunology, and translational medicine, Cullinan is dedicated to innovative strategies that set their therapeutic developments apart. This includes a thorough selection process for therapeutic candidates and an expedited approach to advancing the most promising molecules into clinical trials.
Innovative Strategies and Development Focus
The team at Cullinan Therapeutics combines creativity with a sense of urgency in their development efforts. They are committed to challenging conventional boundaries and apply strict criteria to evaluate therapeutic candidates at every stage of development. This approach ensures that only the most promising candidates progress to clinical trials and, ultimately, to commercialization.
Their primary focus is on delivering innovative therapeutic solutions that aim to enhance outcomes for patients facing difficult medical challenges.
Company Contacts
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
Frequently Asked Questions
What is the focus of Cullinan Therapeutics?
Cullinan Therapeutics is focused on developing targeted therapies that are modality-agnostic for various diseases, including autoimmune disorders and cancer.
Who will be participating in the investor conferences?
Nadim Ahmed, the CEO, and Jeffrey Jones, the CMO, will be participating in the upcoming investor conferences.
How can one access the webcasts of the events?
The webcasts will be available in the Events and Presentations section of the Company’s official investor relations website.
What does the name 'Cullinan' signify?
The name 'Cullinan' symbolizes the company's commitment to excellence and innovation in therapeutic development, akin to the famous Cullinan diamond.
How does Cullinan Therapeutics set its products apart?
Cullinan differentiates its products by focusing on best-in-class development and applying rigorous evaluation criteria at each stage to ensure that only the most effective therapies are advanced.
